You are here

  • Home
  • Online First
  • Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Article info

Article menu

other Versions

Download PDFPDF
Original Article
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Authors

  1. Correspondence to Dr Domenica Lorusso, Fondazione Policlinico Universitario A Gemelli IRCCS Largo Francesco Vito 1, Rome 00168, Italy; domenica.lorusso{at}policlinicogemelli.it
View Full Text

Citation

Lorusso D, Hilpert F, González Martin A On behalf of the PENELOPE trial investigators, et al
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
International Journal of Gynecologic Cancer Published Online First: 15 August 2019. doi: 10.1136/ijgc-2019-000370

Publication history

  • Received February 23, 2019
  • Revision received May 15, 2019
  • Accepted May 29, 2019
  • First published August 15, 2019.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.